The compounds identified in this study are promising candidates for the development of new anticancer drugs via GLUT3, GLUT1, and GLUT4 inhibition, as these inhibitors exhibit different selectivity and affinity for these three transporters, which are overexpressed in many cancers. This evidence concerns the gene SLC2A3 and cancer.